DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS TheracosBio has partnered with the Mark Cuban Cost Plus Drug Company to distribute Brenzavvy.
Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 inhibitor, recently received approval for use as an adjunct to diet and exercise to enhance glycemic control in adult type 2 diabetes patients. This significant stride in the diabetes therapy market emanates from the TheracosBio program and is anticipated to lower treatment cost barriers, thereby expanding utilization.
Key Points:
- Brenzavvy, backed by data from 23 clinical trials involving more than 5,000 adults with type 2 diabetes, is now approved.
- The drug is administered as a 20mg tablet, once daily in the morning.
- Renal function and volume status should be assessed before initiating Brenzavvy treatment; it’s not recommended for patients with an eGFR less than 30mL/min/1.732 and contraindicated in dialysis patients.
Additional Points:
- A 30-day supply of Brenzavvy is priced at $47.85 plus shipping and handling.
Conclusion:
- The launch of Brenzavvy heralds the first phase of TheracosBio’s mission to bring cost-effective novel medications to the US population.
Endocrinology Latest Posts
- Is Anti-Suicidality Next on the GLP-1 Dropdown Menu?
- Oral PCSK9 Inhibitor Tied to LDL-C Drop
- To Keep Your Heart Healthy, Try Drinking More Orange Juice
- Effect of Interventions Aimed at Reducing or Modifying Saturated Fat Intake on Cholesterol, Mortality, and Major Cardiovascular Events
“The commercialization of Brenzavvy marks the first phase of the TheracosBio program to bring cost-effective novel medications to the US population, expanding markets by reducing barriers to greater utilization.”
Albert R. Collinson, PhD
President and CEO
TheracosBio
